Clinical trials: Schizophrenia and Schizophrenia Spectrum Psychosis, open to volunteers
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Schizophrenia and Schizophrenia Spectrum Psychosis
Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizophrenia
This research project aims to evaluate the prevalence of comorbid OSA and its impact on disease progression among hospitalized schizophrenia patients using non-wearable devices.
- Trial name
- IUNWD (NCT07192042)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Psychosis, Schizophrenia Spectrum Disorders
A Case Series of Culturally-adapted CBTp for Black People in the UK
The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis.
- Trial name
- NCT07252206
- Testing
- Culturally-adapted cognitive-behavioural therapy
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Manchester
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder.
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder
- Trial name
- BICEPS (NCT06740383)
- Where
- 6 sites in United States
- Volunteers
- 320 people
- Sponsor
- Beth Israel Deaconess Medical Center
Psychosis, Psychotic Disorders
Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized.
- Conditions
- Psychosis, Psychotic Disorders, Primary Psychotic Disorders, Schizophrenia Spectrum Disorders
- Trial name
- KISO (NCT07395206)
- Testing
- Digital: Kiso Mind App
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia and Schizophrenia Spectrum Psychosis
Feeling Safe Study
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.
- Trial name
- NCT07234708
- Testing
- Sentirnos Seguros
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cardio Vascular Disease, Metabolic Syndrome (MetS)
Norwegian Mental Illness Heart Health Study
Norwegian patients with severe mental illnesses (SMI), such as schizophrenia spectrum or bipolar disorder, lose on average 10 years of life compared to mentally healthy individuals. Much of this gap is due to heart disease.
- Conditions
- Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder, Schizophrenia and Schizophrenia Spectrum Psychosis
- Trial name
- NORMI-Heart (NCT07085923)
- Testing
- Lifestyle Intervention
- Where
- Norway
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Madeleine Elisabeth Angelsen